Given the multifactorial nature of AD, there is growing consensus that multi-targeted therapeutic approaches, which simultaneously address Aβ and tau pathology, neuroinflammation, and oxidative stress, are crucial for advancing disease management [9,10,11]. Here, MAPT is linked to Alzheimer disease.